All stock lists
Solid Biosciences Inc. (NASDAQ:SLDB)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
5.81-0.11 (-1.86%)
Market cap
$623M
Health Score
Analyst consensus
Listed since
Jan 26, 2018
Website
Insider Score
––Not scored
SLDB Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
SLDB analyst forecast
SLDB analyst consensus
Moderate Buy3 ratings
Buy 3 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
SLDB 12-month price target
$18.00+209.8% upsideaverage of 4 firms
$20.00High
$16.00Low
Best analysts covering SLDB
- Wedbush100%success rate · 2 calls
- HC Wainwright & Co.55%success rate · 11 calls
- JP Morgan50%success rate · 4 calls
- Chardan Capital43%success rate · 7 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
SLDB analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| RBC Capital | — | $18.00 | +115.1% | — | 2026-09-16 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-09-14 |
| — | Cantor Fitzgerald | Overweight | — | — | Reiterated | 2026-08-27 |
| — | Truist Securities | Buy | — | — | Reiterated | 2026-08-21 |
| Truist Financial | — | $20.00 | +119.8% | — | 2026-08-21 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-06-03 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-05-18 |
| Piper Sandler | Overweight | $18.00 | +133.2% | Reiterated | 2026-05-13 | |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-05-13 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-03-25 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-03-23 |
| — | Needham | Buy | — | — | Reiterated | 2026-03-20 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2026-03-20 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-03-12 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2026-03-12 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-03-11 |
| — | Needham | Buy | — | — | Reiterated | 2026-02-09 |
| — | Needham | Buy | — | — | Reiterated | 2026-01-14 |
| Needham | — | $16.00 | +208.3% | — | 2025-12-04 | |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-11-05 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-11-05 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-11-04 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-11-04 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-08-14 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-08-14 |
| — | Wedbush | Outperform | — | — | Reiterated | 2025-08-13 |
| Cantor Fitzgerald | — | $16.00 | +136.7% | — | 2025-07-21 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-06-17 |
| — | JMP Securities | Market Outperform | — | — | Reiterated | 2025-06-06 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-05-19 |
| — | Wedbush | Outperform | — | — | Reiterated | 2025-05-16 |
| — | Barclays | Overweight | — | — | Reiterated | 2025-05-16 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2025-05-16 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2025-03-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-03-10 |
| — | Citizens Capital Markets | Market Outperform | — | — | Reiterated | 2025-03-07 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-03-07 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2025-02-19 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2025-01-10 |
| — | HC Wainwright& Co. | Buy | — | — | Reiterated | 2024-12-12 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-12-12 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2024-11-12 |
| — | Chardan Capital | Buy | — | — | Reiterated | 2024-11-11 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-11-07 |
| — | Barclays | Overweight | — | — | Reiterated | 2024-08-14 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-08-14 |
| — | JP Morgan | Overweight | — | — | Upgraded | 2024-07-15 |
| Leerink Partners | Outperform | $12.00 | +81.3% | Upgraded | 2024-06-24 | |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2024-06-21 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2024-05-31 |
| Piper Sandler | — | $20.00 | +161.8% | — | 2024-05-31 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-05-20 |
| Barclays | Overweight | $18.00 | +85.8% | Reiterated | 2024-05-16 | |
| — | Barclays | Overweight | — | — | Reiterated | 2024-03-18 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-03-14 |
| — | Piper Sandler | Overweight | — | — | Upgraded | 2024-03-14 |
| Raymond James | — | $20.00 | +63.5% | — | 2024-03-13 | |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2024-03-11 |
| — | Piper Sandler | Neutral | — | — | Reiterated | 2022-11-11 |
SLDB earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-03-19 | -0.51 | -0.50 | $0 | $0 |
| 2026-05-12 | -0.40 | -0.52 | $0 | $0 |
| 2026-08-06 | -0.46 | -0.38 | $0 | $0 |
| 2026-11-02 | -0.37 | 0.00 | $0 | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.